This site has been optimized to work with modern browsers and does not fully support your version of Internet Explorer.

New information on dosage – work by University of Oxford’s Department of Psychiatry

New analysis shows the lower range of the licensed dose of the most commonly used second-generation antidepressants achieves the optimal balance between efficacy, tolerability and acceptability in the acute treatment of adults with major depression.

Clinical guidelines for antidepressant dosage must reflect the evidence

A new study from Department of Psychiatry, Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis, was published in The Lancet Psychiatry.It demonstrates important clinical implications for guidelines and the daily use of antidepressants in real world settings.

The study focused on the most frequently prescribed antidepressants in the UK, including five SSRIs (selective serotonin reuptake inhibitors: citalopram, escitalopram, fluoxetine, paroxetine and sertraline), venlafaxine and mirtazapine. Data from 19,364 participants was used to assess efficacy, acceptability and tolerability over a median of 8 weeks treatment.

Read more (Department of Psychiatry website)

Copyright 2019 © Oxford Academic Health Science Centre
DEBUG